PALO ALTO, Calif. , Aug. 21, 2024 /PRNewswire/ -- Neuvivo, a biopharmaceutical company developing breakthrough novel therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, today announced the appointment of Matthew William Davis , MD, RPh, as its new Chief Medical Officer.
Ari Azhir , PhD, Founder and CEO of Neuvivo, commented, "I am delighted to have Dr. Davis join our leadership team as he brings extensive experience navigating the regulatory approval process for various neurodegenerative diseases. This aligns nicely as we advance NP001 toward FDA submission.
Dr. Davis also brings exceptional experience with preparing rare disease products for commercialization. His added passion for people with ALS and the advancement of transformative treatments will be essential for leading our medical efforts as we continue to progress in our journey to make a difference.
" "The most rewarding professional experience of my career was securing FDA approval for a familial Mediterranean fever treatment, which has enabled people living with this potentially fatal disease to live a normal lifespan," said Dr. Davis. "I see the same dire need in the ALS community, and I am committed to working with Neuvivo's leadership team to advance NP001 and bring new hope to families grappling with ALS.
" Dr. Davis has spearheaded FDA approval of QWO ® , Lidoderm ® and Colcrys ® , as well as FDA clearance of Sculptra ® . For the past 20 years, he has held the titles of Ch.